Evidence map›Paper›PMID 29260466›Full record

ReviewCNS drugs2017

Targeting Neuroinflammation to Treat Alzheimer's Disease.

A Ardura-Fabregat, E W G M Boddeke, A Boza-Serrano, S Brioschi, S Castro-Gomez, K Ceyzériat, C Dansokho, T Dierkes, G Gelders, Michael T Heneka and 21 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 226 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. AR71, Histamine HInternational journal of molecular sciences · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 18 institutions in 7 countries.

A Ardura-FabregatFaculty of Medicine, Institute of Neuropathology, University of Freiburg, Freiburg, Germany.
E W G M BoddekeDepartment of Neuroscience, Section Medical Physiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
A Boza-SerranoExperimental Neuroinflammation Laboratory, Department of Experimental Medical Sciences, Biomedical Centrum (BMC), Lund University, Lund, Sweden.
S BrioschiDepartment of Psychiatry and Psychotherapy, Medical Center University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg, Germany.
S Castro-GomezDepartment of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany.
K CeyzériatCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de la Recherche Fondamentale (DRF), Institut de biologie François Jacob, MIRCen, 92260, Fontenay-aux-Roses, France.
C DansokhoGerman Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany.
T DierkesGerman Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany.
G GeldersDepartment of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium.
Michael T HenekaGerman Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany. michael.heneka@ukbonn.de.
L HoeijmakersCenter for Neuroscience (SILS-CNS), Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
A HoffmannDepartment of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
L IaccarinoVita-Salute San Raffaele University, Milan, Italy.
S JahnertDepartment of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany.
K KuhbandnerDepartment of Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
G LandrethStark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
N LonnemannDepartment of Cellular Neurobiology, Zoological Institute, Technische Universität Braunschweig, Braunschweig, Germany.
P A LöschmannPfizer Deutschland GmbH, Berlin, Germany.
R M McManusGerman Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany.
A PaulusExperimental Neuroinflammation Laboratory, Department of Experimental Medical Sciences, Biomedical Centrum (BMC), Lund University, Lund, Sweden.
K ReemstCenter for Neuroscience (SILS-CNS), Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
J M Sanchez-CaroGerman Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany.
A TiberiBio@SNS Laboratory, Scuola Normale Superiore, Piazza dei Cavalieri 7, 56126, Pisa, Italy.
A Van der PerrenDepartment of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium.
A VauthenyCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de la Recherche Fondamentale (DRF), Institut de biologie François Jacob, MIRCen, 92260, Fontenay-aux-Roses, France.
C VenegasDepartment of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany.
A WebersDepartment of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany.
P WeydtDepartment of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany.
T S WijasaGerman Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany.
X XiangBiomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, 81377, Munich, Germany.
Y YangExperimental Neuroinflammation Laboratory, Department of Experimental Medical Sciences, Biomedical Centrum (BMC), Lund University, Lund, Sweden.
German Center for Neurodegenerative Diseases · DEUniversity of Bonn · DELund University · SEKU Leuven · BEUniversity of Freiburg · DECEA Paris-Saclay - Etablissement de Fontenay-aux-roses · FRCentre National de la Recherche Scientifique · FRFriedrich-Alexander-Universität Erlangen-Nürnberg · DEIndiana University School of MedicineLudwig-Maximilians-Universität München · DENetherlands Institute for Neuroscience · NLPfizer (Germany) · DEScuola Normale Superiore · ITTechnische Universität Braunschweig · DEUniversitätsklinikum Erlangen · DEUniversity of Amsterdam · NLUniversity of Groningen · NLVita-Salute San Raffaele University · IT

Funding

Actions of Nuclear Receptors on TREM2+ myeloid cells and microglia in AD brainRF1AG050597 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LANDRETH, GARY E. · 2016 to 2016
$2.0M
NIA NIH HHS RF1 AG050597
6 · The paper itself

Abstract

Over the past few decades, research on Alzheimer's disease (AD) has focused on pathomechanisms linked to two of the major pathological hallmarks of extracellular deposition of beta-amyloid peptides and intra-neuronal formation of neurofibrils. Recently, a third disease component, the neuroinflammatory reaction mediated by cerebral innate immune cells, has entered the spotlight, prompted by findings from genetic, pre-clinical, and clinical studies. Various proteins that arise during neurodegeneration, including beta-amyloid, tau, heat shock proteins, and chromogranin, among others, act as danger-associated molecular patterns, that-upon engagement of pattern recognition receptors-induce inflammatory signaling pathways and ultimately lead to the production and release of immune mediators. These may have beneficial effects but ultimately compromise neuronal function and cause cell death. The current review, assembled by participants of the Chiclana Summer School on Neuroinflammation 2016, provides an overview of our current understanding of AD-related immune processes. We describe the principal cellular and molecular players in inflammation as they pertain to AD, examine modifying factors, and discuss potential future therapeutic targets.

Indexed as

Molecular Targeted TherapyAlzheimer DiseaseAmyloid beta-PeptidesAnimalsHumansImmunity, InnateInflammationAmyloid beta-Peptides

Identifiers

PMID29260466
PMCPMC5747579
OpenAlexW2777733505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.